Home › NDC Lookup › Ingredients › Brompheniramine Maleate, Pseudoephedrine... › 71930-0026-43
🧴image loading
(from DailyMed)

Brompheniramine maleate, pseudoephedrine hydrochloride, 2 mg/5mL; 30 mg/5mL; 10 mg/5mL Syrup, 473 mL — NDC 71930-026-43 (Billing 71930-0026-43)

by Eywa Pharma Inc · 473 mL in 1 BOTTLE

This is a package of 473 mL of Brompheniramine maleate, pseudoephedrine hydrochloride, 2 mg/5mL; 30 mg/5mL; 10 mg/5mL Syrup from Eywa Pharma Inc, marketed since Jun 2020 and currently FDA-listed; retail pharmacies pay about $0.0682 per mL (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 71930-0026-43
🏷️ FDA NDC (as labeled) 71930-026-43 billing pads the product segment with a zero
This package
Contains473 mL Cost per mL$0.0682 NADAC Per package$32.26 / 473 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.1064/unit — full pricing hub ↓
Main listing for product 71930-026 · Also comes in: 118 ml 71930-026-18
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Aug 27, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 71930-026-43 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
71930 labeler · 026 product · 43 package
Package marketed since
Jun 26, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
473 mL per package
Barcode (UPC)
0371930026188, 0371930026430
Medicaid fills, this package
116,652 prescriptions in the last four reported quarters
FDA record last changed
Aug 27, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 71930-026-43
Product NDC 71930-026
11-digit billing NDC 71930002643
NCPDP billing unit ML — per mL (volume)
RxCUI 1357010
UNII IXA7C9ZN03, 6V9V2RYJ8N, 9D2RTI9KYH
UPC 0371930026188, 0371930026430
Application # ANDA211170
SPL Set ID 8a4b2d13-d1c9-416f-95fd-f7d7b7970bb5
Established class (EPC) Sigma-1 Agonist; Uncompetitive N-methyl-D-aspartate Receptor Antagonist; alpha-Adrenergic Agonist
Mechanism of action Adrenergic alpha-Agonists; Sigma-1 Receptor Agonists; Uncompetitive NMDA Receptor Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-06-26
Route ORAL
Dosage form SYRUP
Substance BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
TE code (Orange Book) AA · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 43995803321210
GPI class Pseudoeph-Bromphen-DM
GCN Seq No 000909
GCN 96136
HICL code 000389
Ingredient (HICL) Brompheniramine/Pseudoephed/Dm
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B3
Therapeutic class — intermediate (HIC2) Drugs Affecting Primarily The Trachea And Bronchi
HIC3 code B3R
Therapeutic class — specific (HIC3) Non-Opioid Antitus-1St Gen.antihistamine-Decongest
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name BROMPHEN-PSE-DM 2-30-10 MG/5ML
FDB brand name Brompheniramine-Pseudoephed-Dm
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 000909
  • GCN: 96136
  • GPI-14 (Medi-Span): 43995803321210
  • HICL (First Databank): 000389
  • AHFS class code: 12:12.12.00
  • RxCUI (RxNorm): 1357010
Why two NDCs? The FDA registers this code as 71930-026-43 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 71930-0026-43. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Substituted alkylamines class.

Drug family (ATC) Substituted alkylamines
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name BROMPHEN-PSE-DM 2-30-10 MG/5ML Ingredient Brompheniramine/Pseudoephed/Dm

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.068 $32.26 / 473 ml
Medicaid paysCMS SDUD · 12 mo $0.1064 $50.33 / 473 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.099 $0.050
▲ Up 32% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
71930-0026-18 71930-026-18 118 mL in 1 BOTTLE — — 2020-06-26 — Discontinued by firm
71930-0026-43 You're viewing this Main listing 473 mL in 1 BOTTLE $0.0682 / mL $32.28 2020-06-26 — Active

You're viewing the largest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 473 mL — 473 ml in 1 bottle.
How does this package differ from NDC 71930-0026-18?
Both are Brompheniramine maleate, pseudoephedrine hydrochloride, 2 mg/5mL; 30 mg/5mL; 10 mg/5mL Syrup — the drug itself is identical. This page's package is the 473 mL one, while NDC 71930-0026-18 is the 118 ml package.
What NDC number is used to bill for this package of Brompheniramine maleate, pseudoephedrine hydrochloride, 2 mg/5mL; 30 mg/5mL; 10 mg/5mL Syrup?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 62135-0302-47 Chartwell 473 ml $0.068 AA Availability likely —
Brompheniramine, Pseudoephedrine, Dextromethorphan 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 67877-0558-16 Ascend 473 ml $0.068 AA Availability likely —
Brompheniramine maleate, pseudoephedrine hydrochloride, 2 mg/5mL; 30 mg/5mL; 10 mg/5mLthis 71930-0026-43 Eywa 473 ml $0.068 AA Availability likely —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 00121-0933-04 PAI 118 ml $0.082 AA Availability likely +20%
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 00574-1104-04 Padagis 118 ml $0.082 AA Availability likely +20%
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 42192-0607-04 Acella 118 ml $0.082 AA Availability likely +20%
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 42192-0630-04 Acella 118 ml $0.082 AA Availability likely +20%
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide 10 mg/5mL; 30 mg/5mL; 2 mg/5mL 69452-0478-55 BIONPHARMA 118 ml $0.082 AA Availability likely +20%
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 75907-0207-04 Dr. 118 ml $0.082 AA Availability likely +20%
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 50090-5625-00 A-S 118 ml — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 63187-0664-04 Proficient 118 ml — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 63187-0930-04 Proficient 118 ml — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 63629-8615-01 Bryant 118 ml — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 63629-8616-01 Bryant 473 ml — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 68999-0302-24 Chartwell 10 cups — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 70518-4526-00 REMEDYREPACK 3 cups — AA FDA listed —
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide 2 mg/5mL; 30 mg/5mL; 10 mg/5mL 72162-1123-02 Bryant 118 ml — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Jun 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Pink
FlavorButterscotch
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerEywa Pharma Inc
Application holderHIBROW HEALTHCARE PRIVATE LTD
FDA applicationANDA211170 (ANDA)
Labeler code71930
First marketedJun 2020
Product typeHuman Prescription Drug
Portfolio30 products on file

More NDCs from Eywa Pharma Inc labeler code 71930

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 21 words ▾

INDICATIONS AND USAGE For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

⏱️ Dosage and Administration 75 words ▾

DOSAGE AND ADMINISTRATION Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician. Do not exceed 6 doses during a 24-hour period.

⛔ Contraindications 59 words ▾

CONTRAINDICATIONS Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors (see PRECAUTIONS - Drug Interactions). Antihistamines should not be used to treat lower respiratory tract conditions including asthma.

⚠️ Warnings 29 words ▾

WARNINGS Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death. Antihistamines may diminish mental alertness. In the young child, they may produce excitation.

🤒 Adverse Reactions 94 words ▾

ADVERSE REACTIONS The most frequent adverse reactions to brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness. Other adverse reactions may include: Dermatologic: Urticaria, drug rash, photosensitivity, pruritus. Cardiovascular System : Hypotension, hypertension, cardiac arrhythmias, palpitation.

CNS: Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness, convulsions, headache, euphoria, and dysphoria. G.U. System: Urinary frequency, difficult urination.

G.I. System: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation. Respiratory System: Tightness of chest and wheezing, shortness of breath.

Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

🔄 Drug Interactions 94 words ▾

Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS).

Central nervous system (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.) Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.

🤰 Pregnancy 105 words ▾

Pregnancy Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup. It is also not known whether brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.

Reproduction studies of brompheniramine maleate (a component of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.

🧒 Pediatric Use 22 words ▾

Pediatric Use Safety and effectiveness in pediatric patients below the age of 6 months have not been established (see DOSAGE AND ADMINISTRATION).

🧓 Geriatric Use 99 words ▾

Geriatric Use Clinical studies of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients. The elderly are also more likely to experience adverse reactions to sympathomimetics.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🆘 Overdosage ~1 min read ▾

OVERDOSAGE Signs and Symptoms Central nervous system effects from overdosage of brompheniramine may vary from depression to stimulation, especially in children. Anticholinergic effects may be noted. Toxic doses of pseudoephedrine may result in CNS stimulation, tachycardia, hypertension, and cardiac arrhythmias; signs of CNS depression may occasionally be seen.

Dextromethorphan in toxic doses will cause drowsiness, ataxia, nystagmus, opisthotonos, and convulsive seizures. Toxic Doses Data suggest that individuals may respond in an unexpected manner to apparently small amounts of a particular drug. A 2½-year-old child survived the ingestion of 21 mg/kg of dextromethorphan exhibiting only ataxia, drowsiness, and fever, but seizures have been reported in 2 children following the ingestion of 13-17 mg/kg.

Another 2½-year-old child survived a dose of 300-900 mg of brompheniramine. The toxic dose of pseudoephedrine should be less than that of ephedrine, which is estimated to be 50 mg/kg. Treatment Induce emesis if patient is alert and is seen prior to 6 hours following ingestion.

Precautions against aspiration must be taken, especially in infants and small children. Gastric lavage may be carried out, although in some instances tracheostomy may be necessary prior to lavage. Naloxone hydrochloride 0.005 mg/kg intravenously may be of value in reversing the CNS depression that may occur from an overdose of dextromethorphan.

CNS stimulants may counter CNS depression.Should CNS hyperactivity or convulsive seizures occur, intravenous shortacting barbiturates may be indicated. Hypertensive responses and/or tachycardia should be treated appropriately. Oxygen, intravenous fluids, and other supportive measures should be employed as indicated.

🧬 Clinical Pharmacology 197 words ▾

CLINICAL PHARMACOLOGY Brompheniramine maleate is a histamine antagonist, specifically an H1-receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic (drying) and sedative effects.

Among the antihistaminic effects, it antagonizes the allergic response (vasodilation, increased vascular permeability, increased mucus secretion) of nasal tissue. Brompheniramine is well absorbed from the gastrointestinal tract, with peak plasma concentration after single, oral dose of 4 mg reached in 5 hours; urinary excretion is the major route of elimination, mostly as products of biodegradation; the liver is assumed to be the main site of metabolic transformation. Pseudoephedrine acts on sympathetic nerve endings and also on smooth muscle, making it useful as a nasal decongestant.

The nasal decongestant effect is mediated by the action of pseudoephedrine on α- sympathetic receptors, producing vasoconstriction of the dilated nasal arterioles. Following oral administration, effects are noted within 30 minutes with peak activity occurring at approximately one hour. Dextromethorphan acts centrally to elevate the threshold for coughing.

It has no analgesic or addictive properties. The onset of antitussive action occurs in 15 to 30 minutes after administration and is of long duration.

📦 How Supplied / Storage and Handling 111 words ▾

HOW SUPPLIED Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is a clear, light pink-colored, butterscotch-flavored syrup containing in each 5 mL (1 teaspoonful) brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg and dextromethorphan hydrobromide 10 mg, available in the following sizes: 4 fl oz (118 mL) NDC 71930-026-18 1 pint (473 mL) NDC 71930-026-43 RECOMMENDED STORAGE Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. KEEP TIGHTLY CLOSED Dispense in a tight, light-resistant container as defined in the USP Rx Only Manufactured by: WES Pharma Inc Westminster, MD – 21157 USA Distributed by: Eywa Pharma Inc., 2 Research Way, Floor 3, Princeton, NJ 08540 REV.

04/20

📋 Description 130 words ▾

DESCRIPTION Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup, 2 mg/30 mg/10 mg per 5 mL is a clear, light pink syrup with a butterscotch flavour. Each 5 mL (1 teaspoonful) contains: Brompheniramine Maleate, USP 2 mg Pseudoephedrine Hydrochloride, USP 30 mg Dextromethorphan Hydrobromide, USP 10 mg Alcohol 0.95% v/v In a palatable, aromatic vehicle. Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, alcohol, FD&C Red No.

40, glycerin, sucrose, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 4.0 and 6.0.

Brompheniramine Maleate, USP(±)-2- p -Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1) Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α-morphinan hydrobromide monohydrate Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration. bromfed-str1 bromfed-str2 bromfed-str3

💬 Information for Patients 23 words ▾

Information for Patients Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating dangerous machinery.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Because of its antihistamine component, brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup should be used with caution in patients with a history of bronchial asthma, narrow angle glaucoma, gastrointestinal obstruction, or urinary bladder neck obstruction. Because of its sympathomimetic component, brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup should be used with caution in patients with diabetes, hypertension, heart disease, or thyroid disease.

Information for Patients Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating dangerous machinery. Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine.

Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central nervous system (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.) Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies of Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have not been performed.

Pregnancy Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup. It is also not known whether brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.

Reproduction studies of brompheniramine maleate (a component of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus. Nursing Mothers Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is contraindicated in nursing mothers.

Pediatric Use Safety and effectiveness in pediatric patients below the age of 6 months have not been established (see DOSAGE AND ADMINISTRATION). Geriatric Use Clinical studies of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

The elderly are also more likely to experience adverse reactions to sympathomimetics. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🍼 Nursing Mothers 35 words ▾

Nursing Mothers Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is contraindicated in nursing mothers.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 32 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies of Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have not been performed.

📄 Package Label / Principal Display Panel 15 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 4 fl oz (118 mL) 1 pint (473 mL) bromfed-label118 bromfed-label2

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
116.7K
Units reimbursed last 4 qtrs
19M
Gross reimbursed last 4 qtrs
$2.02M
Avg / prescription
$17.32
Avg / unit
$0.1064
Latest quarter Q1 2026
39.7KRx
Medicaid pays / mL
$0.1064
gross reimbursed
vs
NADAC / mL
$0.0682
acquisition cost
=
Spread
+$0.0382
+56% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
96% MCO
Fee-for-service · 5,027 Rx Managed care · 111,625 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 23,207 units · 231 per 100k residents MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 11,177 units · 350 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 251,835 units · 3,670 per 100k residents IN Ohio: 1,077,495 units · 9,143 per 100k residents OH Pennsylvania: 53,549 units · 413 per 100k residents PA New Jersey: 436,617 units · 4,700 per 100k residents NJ Massachusetts: no data reported MA California: 617,119 units · 1,584 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 1,180,709 units · 26,087 per 100k residents KY West Virginia: 49,964 units · 2,823 per 100k residents WV Virginia: 13,504 units · 155 per 100k residents VA Maryland: 98,459 units · 1,593 per 100k residents MD Connecticut: 2,373 units · 65.6 per 100k residents CT Rhode Island: no data reported RI Arizona: 2,965 units · 39.9 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 1,231 units · 17.3 per 100k residents TN North Carolina: no data reported NC South Carolina: 146,700 units · 2,730 per 100k residents SC Delaware: 13,314 units · 1,291 per 100k residents DE Oklahoma: no data reported OK Louisiana: 4,360 units · 95.3 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 109,887 units · 996 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 14,268,915 units · 46,779 per 100k residents TX Florida: 625,362 units · 2,766 per 100k residents FL
Units reimbursed · per 100k residents
17.346,779
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Texas 46,779 /100k
2 Kentucky 26,087 /100k
3 Ohio 9,143 /100k
4 New Jersey 4,700 /100k
5 Indiana 3,670 /100k
6 West Virginia 2,823 /100k
7 Florida 2,766 /100k
8 South Carolina 2,730 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
473 ml this page71930-0026-43 116,652 Rx · $2,019,921
118 ml71930-0026-18 No Medicaid data
Drug total (last 4 qtrs): 116,652 Rx · 18,988,740 units · $2,019,921 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 71930-0025-52 · Eywa 71930-0027-43 · Eywa →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.